Ocu410

Phase 3

OOcugen

Ocu410 is one of 36 therapeutic programs targeting Age-Related Macular Degeneration. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Age-Related Macular DegenerationPhase 3

Recruiting

Competition

Competitive Landscape

43 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Eylea

Regeneron

Approved

40 2

Zometa

Bayer Aspirin

Plavix

Tecfidera

Visudyne

BBausch Health Americas, Inc.

Approved

1 7

Lodosyn

LLaTonya J. Hickson

Approved

—8

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—9

Acetadote

AArbor Pharmaceuticals, Inc.

Approved

—10

Bendopa

MMerz North America, Inc.

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2031

Phase 3Recruiting

Age-Related Macular Degeneration

NCT07770828

Clinical

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

A Phase 3 Registrational Study To Assess The Efficacy, Safety, And Tolerability Of OCU410 For Geographic Atrophy Secondary To Dry Age-Related Macular Degeneration

Recruiting·OOcugen·Phase 3·NCT07770828·237 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Ocu410. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Ocu410. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Ocugen company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: OOcugen

Ocu410

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2031

Trials by Indication[1]

Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News